

Contents

Section: Dedication and Introduction by Carl Erik Mogensen	v
Aperitif by Edwin Gale, UK	vii
Contributors	xiii
 Section: Overview	
1. Pharmacoepidemiology of Diabetes	3
<i>Jørgen Rungby and Andrew J. Krentz</i>	
2. New Definitions of Diabetes: Consequences	9
<i>Knut Borch-Johnsen</i>	
 Section: Pharmacotherapy of Diabetes	
3. The Insulin Resistance Syndrome: Concept and Therapeutic Approaches	19
<i>Gerald M. Reaven</i>	
4. Medical Emergencies – Diabetic Ketoacidosis and Hyperosmolar Hyperglycaemia	31
<i>Niels Møller and K. George M.M. Alberti</i>	
5. Notes on the Use of Glucagon in Type 1 Diabetes	39
<i>Carl Erik Mogensen</i>	
6. Insulin and New Insulin Analogues, Insulin Pumps and Inhaled Insulin in Type 1 Diabetes	41
<i>Kjeld Hermansen</i>	
7. Insulin and New Insulin Analogues with Focus on Type 2 Diabetes	53
<i>Sten Madsbad</i>	
8. The Place of Insulin Secretagogues in the Treatment of Type 2 Diabetes in the Twenty-First Century	67
<i>Harald Stingl and Guntram Schernthaner</i>	

9.	Metformin – from Devil to Angel	77
	<i>Guntram Schernthaner and Gerit Holger Schernthaner</i>	
10.	The Glitazones, Lessons so Far	87
	<i>Monika Shirodkar and Serge Jabbour</i>	
11.	Antidiabetic Combination Therapy	99
	<i>Henning Beck-Nielsen and Jan Erik Henriksen</i>	
12.	The Incretin Modulators – Incretin Mimetics (GLP-1 Receptor Agonists) and Incretin Enhancers (DPP-4 Inhibitors)	111
	<i>Michael A. Nauck, Wolfgang E. Schmidt, and Juris J. Meier</i>	
13.	The Role of Alpha-Glucosidase Inhibitors (Acarbose)	143
	<i>Markolf Hanefeld and Frank Schaper</i>	
14.	Multifactorial Intervention in Type 2 Diabetes	153
	<i>Oluf Pedersen</i>	
Section: Treating the Comorbid Patient		
15.	Obesity and Pharmacological Treatment	167
	<i>Bjørn Richelsen</i>	
16.	Management of Diabetic Dyslipidaemia.	173
	<i>D. John Betteridge</i>	
17.	Coronary Intervention and Ischemic Cardioprotection in Diabetic Patients.	187
	<i>Torsten Toftegaard Nielsen</i>	
Section: Diabetic Complications and Side-effects		
18.	ACE-I and ARB and Blood Pressure Lowering, Including Effect on Renal Disease. Treatment of Advanced Diabetic Renal Disease.	201
	<i>Per Løgstrup Poulsen and Johan V. Poulsen</i>	
19.	Aspirin and Antiplatelet Drugs in the Prevention of Cardiovascular Complications of Diabetes	211
	<i>Alberto Zanchetti</i>	
20.	Glycosylation Inhibitors, PKC Inhibitors and Related Interventions Against Complications.	219
	<i>Aino Soro-Paavonen and Mark Cooper</i>	
21.	Diabetic Foot Ulcers	229
	<i>Andrew Boulton and Frank Bowling</i>	
22.	Pharmacotherapy in Diabetic Neuropathy	237
	<i>Anders Dejgaard and Jannik Hilsted</i>	

Contents	xi
23. Pregnancy – Pharmacological Problems.	249
<i>Elisabeth R. Mathiesen and Peter Damm</i>	
24. Pharmacotherapy of Diabetic Retinopathy	255
<i>Toke Bek</i>	
25. Pharmacotherapy in Diabetic Sexual Dysfunction	261
<i>Niels Ejskjaer</i>	
26. A Bone Perspective	267
<i>Lars Rejnmark</i>	
 Section: Notes from Major Pharmaceutical Companies	
(all major companies asked to participate)	
27. Achieving Guideline Control with New Pharmacotherapies:	
Albumin-Binding by Acylation of Insulin and GLP-1	273
<i>Mads Krogsgaard Thomsen</i>	
28. Pharmacotherapy of Diabetes.	277
<i>Post Scriptum by the Editor</i>	
Index.	283

